In total, we observed HNF1B expression in 66% of gynecologic and 56% of renal neoplasms with cytoplasmic clearing, compared to 5% and 16%, respectively, without cytoplasmic clearing, and compared to 1% of other neoplasms, all highly significant differences (P<0.001; two-tailed Fisher exact tests) (Fig. 1D, and Table S1). Here, HNF1B is linked to neoplasm.